US 11,773,186 B2
Antibodies to ticagrelor and methods of use
Andrew Buchanan, Cambridge (GB); Sven Nylander, Sodertalje (SE); Mark Penney, Cambridge (GB); Philip Newton, Cambridge (GB); Feenagh Keyes, Cambridge (GB); and Tord Inghardt, Sodertalje (SE)
Assigned to MEDIMMUNE LIMITED, Cambridge (GB)
Filed by MEDIMMUNE LIMITED, Cambridge (GB)
Filed on Feb. 16, 2021, as Appl. No. 17/176,624.
Application 17/176,624 is a division of application No. 16/035,954, filed on Jul. 16, 2018, granted, now 10,954,308, issued on Mar. 23, 2021.
Application 16/035,954 is a division of application No. 15/966,313, filed on Apr. 30, 2018, abandoned.
Application 15/966,313 is a continuation of application No. 14/871,111, filed on Sep. 30, 2015, granted, now 9,982,061, issued on May 29, 2018.
Claims priority of provisional application 62/114,931, filed on Feb. 11, 2015.
Claims priority of provisional application 62/058,458, filed on Oct. 1, 2014.
Prior Publication US 2021/0371546 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/44 (2006.01); C07D 487/04 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/44 (2013.01) [C07D 487/04 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 15 Claims
 
1. An antibody or a fragment thereof that specifically binds a cyclopentyltriazolopyrimidine compound of the Formula (Ia):

OG Complex Work Unit Chemistry
wherein
R1 is selected from the group consisting of C1-C6 alkoxy and C1-C6 alkylthio;
R2 is selected from the group consisting of H, C1-C6 alkyl, substituted C1-C6 alkyl, C3-C6 cycloalkyl, and substituted C3-C6 cycloalkyl; and
R3 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 alkanol;
wherein the antibody or a fragment thereof comprises the complementarity-determining regions (CDR) of:
SEQ ID NO:73 (VH CDR1), SEQ ID NO:74 (VH CDR2), SEQ ID NO:75 (VH CDR3), SEQ ID NO:78 (VL CDR1), SEQ ID NO:79 (VL CDR2), and SEQ ID NO:80 (VL CDR3).